{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:29:41Z","timestamp":1786422581191,"version":"build-2736575974"},"reference-count":26,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.59556\/japi.73.0810","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:08:51Z","timestamp":1750748931000},"page":"29-34","source":"Crossref","is-referenced-by-count":0,"title":["Erdosteine: Reigniting a Thiol Mucolytic for Management of Chronic Obstructive Pulmonary Disease"],"prefix":"10.59556","volume":"73","author":[{"given":"Agam","family":"Vora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmy","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anooja","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Qamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathy","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20250624070848_B1","unstructured":"GOLD. 2024 guidelines for prevention, diagnosis and management of COPD. Available at: https:\/\/goldcopd.org\/2024-goldreport\/ (accessed on 19-09-2024)."},{"issue":"(5):","key":"key20250624070848_B2","doi-asserted-by":"crossref","first-page":"447\u2013","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis.","volume":"10","author":"Adeloye","year":"2022;","journal-title":"Lancet Respir Med"},{"issue":"(13):","key":"key20250624070848_B3","doi-asserted-by":"crossref","first-page":"1257\u2013","DOI":"10.1056\/NEJMra1900500","article-title":"Update on clinical aspects of chronic obstructive pulmonary disease.","volume":"381","author":"Celli","year":"2019;","journal-title":"N Engl J Med"},{"key":"key20250624070848_B4","doi-asserted-by":"crossref","first-page":"15076.","DOI":"10.1038\/nrdp.2015.76","article-title":"Chronic obstructive pulmonary disease.","volume":"1:","author":"Barnes","year":"2015;","journal-title":"Nat Rev Dis Primers"},{"issue":"(17):","key":"key20250624070848_B5","doi-asserted-by":"crossref","first-page":"1799\u2013","DOI":"10.1007\/s40265-020-01412-x","article-title":"Multifaceted beneficial effects of erdosteine: more than a mucolytic agent.","volume":"80","author":"Cazzola","year":"2020;","journal-title":"Drugs"},{"issue":"(3):","key":"key20250624070848_B6","doi-asserted-by":"crossref","first-page":"127\u2013","DOI":"10.1177\/1753465812437563","article-title":"N-acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.","volume":"6","author":"Sadowska","year":"2012;","journal-title":"Ther Adv Respir Dis"},{"issue":"(7):","key":"key20250624070848_B7","doi-asserted-by":"crossref","first-page":"452\u2013","DOI":"10.1016\/j.tips.2019.04.015","article-title":"Thiol-based drugs in pulmonary medicine: much more than mucolytics.","volume":"40","author":"Cazzola","year":"2019;","journal-title":"Trends Pharmacol Sci"},{"key":"key20250624070848_B8","unstructured":"Erdosteine 300 mg capsules SPC available at https:\/\/www.medicines.org.uk\/emc\/product\/287\/smpc#gref (accessed on 29-01-2023)"},{"key":"key20250624070848_B9","doi-asserted-by":"crossref","first-page":"803\u2013","DOI":"10.2147\/COPD.S114423","article-title":"Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.","volume":"12:","author":"Yan","year":"2017;","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"key20250624070848_B10","doi-asserted-by":"crossref","first-page":"80\u2013","DOI":"10.1016\/j.pupt.2018.10.005","article-title":"Erdosteine: drug exhibiting polypharmacy for the treatment of respiratory diseases.","volume":"53:","author":"Dal Negro","year":"2018;","journal-title":"Pulm Pharmacol Ther"},{"issue":"(3):","key":"key20250624070848_B11","doi-asserted-by":"crossref","first-page":"106529.","DOI":"10.1016\/j.ijantimicag.2022.106529","article-title":"Erdosteine enhances antibiotic activity against bacteria within biofilm.","volume":"59","author":"Pani","year":"2022;","journal-title":"Int J Antimicrob Agents"},{"issue":"(4):","key":"key20250624070848_B12","first-page":"219\u2013","article-title":"Prevention of exacerbations in chronic bronchitic patients with erdosteine.","volume":"12","author":"Fioretti","year":"1991;","journal-title":"Med Prax"},{"issue":"(11):","key":"key20250624070848_B13","first-page":"612\u2013","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).","volume":"33","author":"Marchioni","year":"1995;","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"(4):","key":"key20250624070848_B14","first-page":"521\u2013","article-title":"Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion.","volume":"16","author":"Aubier","year":"1999;","journal-title":"Rev Mal Respir"},{"issue":"(4):","key":"key20250624070848_B15","first-page":"143\u2013","article-title":"The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.","volume":"30","author":"Moretti","year":"2004;","journal-title":"Drugs Exp Clin Res"},{"issue":"(9):","key":"key20250624070848_B16","doi-asserted-by":"crossref","first-page":"2001\u2013","DOI":"10.1016\/j.clinthera.2007.09.003","article-title":"Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.","volume":"29","author":"Crisafulli","year":"2007;","journal-title":"Clin Ther"},{"key":"key20250624070848_B17","doi-asserted-by":"crossref","first-page":"2319\u2013","DOI":"10.2147\/COPD.S87091","article-title":"Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.","volume":"10:","author":"Moretti","year":"2015;","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"(4):","key":"key20250624070848_B18","doi-asserted-by":"crossref","first-page":"1700711.","DOI":"10.1183\/13993003.00711-2017","article-title":"Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.","volume":"50","author":"Dal Negro","year":"2017;","journal-title":"Eur Respir J"},{"issue":"(9470):","key":"key20250624070848_B19","doi-asserted-by":"crossref","first-page":"1552\u2013","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in COPD (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.","volume":"365","author":"Decramer","year":"2005;","journal-title":"Lancet"},{"key":"key20250624070848_B20","doi-asserted-by":"crossref","first-page":"2733\u2013","DOI":"10.2147\/COPD.S221852","article-title":"Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation.","volume":"14:","author":"Calverley","year":"2019;","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"key20250624070848_B21","doi-asserted-by":"crossref","first-page":"1909\u2013","DOI":"10.2147\/COPD.S369804","article-title":"The effect of maintenance treatment with erdosteine on exacerbation treatment and health status in patients with COPD: a post-hoc analysis of the RESTORE dataset.","volume":"17:","author":"Calverley","year":"2022;","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"(2):","key":"key20250624070848_B22","doi-asserted-by":"crossref","first-page":"135\u2013","DOI":"10.1016\/j.pupt.2009.10.002","article-title":"The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.","volume":"23","author":"Cazzola","year":"2010;","journal-title":"Pulm Pharmacol Ther"},{"key":"key20250624070848_B23","doi-asserted-by":"crossref","first-page":"185\u2013","DOI":"10.1016\/j.pupt.2017.11.009","article-title":"Impact of erdosteine on chronic bronchitis and COPD: a meta-analysis.","volume":"48:","author":"Cazzola","year":"2018;","journal-title":"Pulm Pharmacol Ther"},{"issue":"(1):","key":"key20250624070848_B24","doi-asserted-by":"crossref","first-page":"104.","DOI":"10.1186\/s12931-019-1078-y","article-title":"Efficacy and safety profile of mucolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.","volume":"20","author":"Rogliani","year":"2019;","journal-title":"Respir Res"},{"key":"key20250624070848_B25","doi-asserted-by":"crossref","first-page":"106190.","DOI":"10.1016\/j.rmed.2020.106190","article-title":"Use of mucolytics in COPD: a Delphi consensus study.","volume":"175:","author":"Papi","year":"2020;","journal-title":"Respir Med"},{"issue":"(1):","key":"key20250624070848_B26","doi-asserted-by":"crossref","first-page":"e002216.","DOI":"10.1136\/bmjresp-2023-002216","article-title":"Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial.","volume":"11","author":"Chang","year":"2024;","journal-title":"BMJ Open Respir Res"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:08:56Z","timestamp":1750748936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-73-1-29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.59556\/japi.73.0810"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.0810","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}